Formulary Decisions

Search for the outcome of decisions made by the Formulary Committee

Filter
Select filter(s)
Buprenorphine + Naloxone
Buprenorphine + naloxone
Routinely available
SMC (355/07)
24/06/2026

Indication

For restricted use within NHS Scotland for substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. Buprenorphine/naloxone is restricted to those patients in whom methadone is not suitable and for whom the use of buprenorphine is considere...

For restricted use within NHS Scotland for substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. Buprenorphine/naloxone is restricted to those patients in whom methadone is not suitable and for whom the use of buprenorphine is considered appropriate.

Therapeutic Area

Central nervous system

Status Description

Routinely available in line with national guidance

Formulation

2mg/0.5mg, 8mg/2mg sublingual tablet

Comments

Refer to pathway or local board guidelines for preferred formulation

Link to Advice

355/07

Advice Published

12/03/2007

SMC Submission Type

Full

SMC Status

Restricted